Biolife solutions leverages expanded bioproduction tools and services portfolio in multipoint engagement with leading car t-cell developer

Bothell, wash., oct. 4, 2021 /prnewswire/ -- biolife solutions, inc. (nasdaq: blfs) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein biolife's cryostor freeze media, evo cold chain management platform and scisafe storage services with stirling ultracold freezers are all being utilized by this top 10 largest global pharmaceutical company to support the anticipated regulatory approval and commercial launch of a new car t-cell therapy.
BLFS Ratings Summary
BLFS Quant Ranking